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ABSTRACT
Pain management is an important part of dental practice, and dentists frequently prescribe 
analgesics to improve clinical outcomes. Dentists should be aware of the pharmacological 
characteristics of the analgesics commonly used in dentistry and should choose appropriate 
analgesics to treat and prevent pain associated with inflammation or surgery. In this article, 
we review the potential benefits and risks of the analgesics frequently used in dental practice 
and provide a stepwise approach for pain management.
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INTRODUCTION
Effective and safe pain management is a primary goal in dental practice. Control of pain 
associated with dental or periodontal disease is a main reason that patients seek care from 
dentists. In addition, many dental procedures are painful, and postoperative pain may persist 
for days. Therefore, dentists should use appropriate analgesics to treat and prevent pain 
associated with inflammation or surgery.
A variety of analgesics are currently available. Analgesics can be classified into opioid and 
non-opioid analgesics. Non-opioid analgesics include non-steroidal anti-inflammatory drugs 
(NSAIDs) and acetaminophen; NSAIDs are further divided into nonselective traditional 
non-steroidal anti-inflammatory drugs (tNSAIDs) and selective cyclooxygenase (COX)-2 
inhibitors (Table 1). The aim of this review was to describe considerations for selecting 
among those analgesics for the management of acute and postoperative dental pain. Drugs 
such as antidepressants and antiepileptics can also be used to manage the symptoms of 
some chronic pain conditions, but these medications will not be discussed in this article (for 
details, see Colloca et al. [1]).
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Dentists often prescribe opioid analgesics, such as hydrocodone, codeine, oxycodone, and 
tramadol, for the management of dental pain. However, opioids may cause various adverse 
effects, such as nausea and vomiting, constipation, urinary retention, respiratory depression, 
sedation, sleep disturbance, dependence, and addiction. In contrast, non-opioid analgesics 
generally have less serious adverse effects than opioid analgesics at therapeutic doses. Although 
historically, the potency and efficacy of non-opioid analgesics have been thought to be lower 
than those of opioids, clinical studies have repeatedly shown that non-opioid analgesics, 
such as ibuprofen, are more effective than opioids in suppressing postoperative dental pain 
[2]. However, if non-opioid analgesics fail to relieve pain, an opioid may be administered 
in conjunction with non-opioid analgesics to provide synergistic analgesia. Therefore, in 
dental practice, rather than being prescribed alone, opioid analgesics are often prescribed in 
combination with acetaminophen or NSAIDs to increase the analgesic effect [3].
NSAIDS
NSAIDs decrease the production of prostaglandins, an effect that is attributed to the 
inhibition of COX. tNSAIDs inhibit both COX-1 and COX-2 to different degrees. These drugs 
have common therapeutic actions, including anti-inflammatory, analgesic, and antipyretic 
actions that are mainly due to the inhibition of COX-2, the expression of which is induced 
by inflammation. In contrast, the inhibition of COX-1 is generally responsible for NSAID-
induced gastropathy, nephropathy, and prolonged bleeding time. Acetaminophen similarly 
has analgesic and antipyretic activities via the inhibition of COX enzymes, but it is technically 
not classified as an NSAID because it has only minimal anti-inflammatory activity, although 
its exact mechanism of action is still unclear [4].
Acetaminophen and tNSAIDs
The tNSAIDs currently available on the market include aspirin, diflunisal, ibuprofen, 
naproxen, ketoprofen, flurbiprofen, indomethacin, sulindac, etodolac, diclofenac, ketorolac, 
piroxicam, mefenamic acid, and nabumetone. To choose the most appropriate analgesics 
for pain relief, dentists should consider both the potential benefits and the risks. From the 
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Table 1. Classification of analgesics used in dental practice
Classification of analgesics
Opioid analgesics




Diflunisal, ibuprofen, naproxen, ketoprofen, loxoprofen, flurbiprofen, indomethacin, sulindac, 
etodolac, diclofenac, ketorolac, piroxicam, meloxicam, mefenamic acid, nabumetone
COX-2 inhibitors (COX-2-selective NSAIDs)
Celecoxib, etoricoxib, polmacoxib
Acetaminophen
Drugs used for neuropathic pain
Pregabalin, gabapentin, duloxetine
NSAIDs: non-steroidal anti-inflammatory drugs, tNSAIDs: traditional non-steroidal anti-inflammatory drugs, COX-2: 
cyclooxygenase-2.
a)In Korea, tramadol is approved as a non-narcotic analgesic.
perspective of benefit-risk analysis, the primary drugs of choice for the relief of dental pain 
are acetaminophen and ibuprofen [5].
Acetaminophen (also known as paracetamol) is one of the most widely used analgesic antipyretic 
drugs and has minimal anti-inflammatory activity. Despite its long history as a painkiller, 
the mechanism of action of acetaminophen is still not completely understood. The current 
understanding is that while tNSAIDs inhibit the COX activity of the COX enzyme, acetaminophen 
inhibits the peroxidase activity of COX at low peroxide levels; this peroxide-dependent inhibition 
of COX allows acetaminophen to act preferentially within the central nervous system without 
peripheral anti-inflammatory activity, as the peroxide level is much higher at peripheral 
inflammatory sites than in the brain [4]. Due to its lack of inhibitory effect on the peripheral COX 
activity, acetaminophen is less likely than tNSAIDs to induce gastrointestinal and cardiovascular 
adverse effects and does not prolong bleeding time. Unlike aspirin, acetaminophen does not 
increase the risk of Reye syndrome, which causes brain and liver damage in children recovering 
from viral infection. Acetaminophen has no noteworthy limitations for use in pregnant women. 
Acetaminophen is therefore especially suitable for patients who do not tolerate tNSAIDs due 
to their adverse effects, such as the increased risk of gastrointestinal ulcer disease. However, 
acetaminophen may cause serious liver damage if excessive quantities of its toxic metabolite 
are generated through the phase I biotransformation induced by the hepatic cytochrome P450 
system. Therefore, this drug should not be taken in excess of 4 g per day (the United States 
Food and Drug Administration recently suggested a maximum daily dose of 3 g), and those 
with serious liver disease or who regularly and continuously consume large volumes of alcohol 
should exercise extra caution. Since patients may unknowingly take acetaminophen combination 
products, dentists should ensure that the patient will not consume too much acetaminophen 
when prescribing the drug. Acetaminophen is used for mild pain and can be combined with 
tNSAIDs and/or opioid analgesics to increase effectiveness.
Ibuprofen is very effective for relieving mild or moderate pain and is one of the most 
frequently prescribed analgesics by dentists. Generally, the analgesic effect of 200 mg of 
ibuprofen is similar to or stronger than that of 500–1,000 mg of acetaminophen. For mild 
dental pain, 200 mg to 400 mg of ibuprofen every 4 to 6 hours is recommended [3,5]. 
Within this dose range, the potential of ibuprofen to cause adverse gastrointestinal, liver, 
or cardiovascular effects is relatively low compared with other tNSAIDs [6]. However, if this 
regimen does not provide sufficient analgesia, the dose may be increased to 400 mg to 600 
mg to provide greater pain relief, and such a dosage increase is accompanied by increased 
gastrointestinal and cardiovascular risks.
Naproxen has a longer duration and a stronger anti-inflammatory effect than ibuprofen. 
However, despite its advantages over ibuprofen, naproxen has a higher risk of adverse 
effects such as gastrointestinal toxicity [7]. Thus, naproxen should be reserved for pain that 
is not relieved by ibuprofen. The gastrointestinal and cardiovascular risks associated with 
acetaminophen, ibuprofen, and naproxen are compared in Table 2.
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Table 2. Gastrointestinal and cardiovascular risks of acetaminophen, ibuprofen, naproxen, and COX-2 inhibitors
Drugs Gastrointestinal risk Cardiovascular risk
Acetaminophen Low Low
Ibuprofen Low to moderate Moderate to high
Naproxen Moderate to high Low to moderate
COX-2 inhibitors Low High
COX-2: cyclooxygenase-2.
Other tNSAIDs, such as diclofenac, ketoprofen, and etodolac, may have analgesic effects 
similar to or stronger than those of ibuprofen or naproxen, but dentists should bear in mind 
that these drugs may also have more adverse gastrointestinal or cardiovascular effects, 
especially when used at high dosages.
Although tNSAIDs are safe if used for a short period of time, they may cause heartburn, 
nausea, vomiting, diarrhea, and in some cases potentially serious adverse effects such as 
gastric ulcer and gastric perforation. This is primarily due to their inhibition of prostaglandin 
production in the gastric mucosa, leading to decreased mucus and bicarbonate generation 
and increased gastric acid secretion. In patients at high risk of gastrointestinal disease, 
therefore, tNSAIDs may be prescribed in combination with mucosal protective agents 
or gastric acid secretion inhibitors, such as proton pump inhibitors. Alternatively, 
acetaminophen or COX-2 inhibitors can be prescribed.
Aspirin irreversibly inhibits COX and thus is distinguished from non-aspirin tNSAIDs, which 
are competitive reversible inhibitors. The irreversible mode of action of aspirin prevents 
thromboxane A2 synthesis by platelets for their circulating lifetime; thus, the antithrombotic 
effect of aspirin may last for 5 to 7 days [8]. Other tNSAIDs reversibly inhibit COX, such that 
the antiplatelet effect of these drugs declines as their plasma concentrations decrease via 
metabolism and excretion. Apart from their antithrombotic effect, tNSAIDs may cause renal 
toxicity because prostaglandins also play a role in the maintenance of renal function; thus, 
dentists should take care when prescribing tNSAIDs to patients with compromised renal 
function [9].
NSAIDs are associated with various drug interactions. For example, tNSAIDs such as 
ibuprofen and naproxen have been reported to interact with aspirin [10]. Many patients with 
cardiovascular diseases take low dose of aspirin regularly (often 81 mg daily) to decrease the 
risk of ischemic heart disease and stroke. If ibuprofen or naproxen is prescribed to patients 
taking aspirin, it will interfere with the antiplatelet effect of aspirin by antagonizing the 
acetylation of COX-1 and will thus reduce aspirin's cardioprotective effects [11,12]. If these 
tNSAIDs are deemed necessary, patients should be informed about this drug interaction 
and should be advised to take aspirin at least 30 minutes prior to taking such tNSAIDs. Drug 
interactions associated with NSAIDs are summarized in Table 3.
Selective COX-2 inhibitors
Inhibition of COX-1 by tNSAIDs is responsible for NSAID-induced gastropathy, nephropathy, 
and prolonged bleeding time. Selective COX-2 inhibitors were developed to avoid the 
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Table 3. Drug interactions associated with NSAIDs
Drugs interacting with NSAIDs Effects
Oral antidiabetic drugs Hypoglycemia may occur.
Low-dose aspirin The cardiovascular protective effects of aspirin may be 
compromised.
ACE inhibitors, β-blockers, and diuretics Blood pressure may increase.
Antiplatelets or anticoagulants Bleeding tendency may increase.
Other NSAIDs NSAID-related adverse effects may increase.
Corticosteroids Adverse gastrointestinal effects may increase.
Methotrexate, lithium, phenytoin, and 
calcium channel blockers
Toxicity may increase due to elevated blood level of these drugs.
Nephrotoxic agents, such as adefovir, 
aminoglycosides, cisplatin, and foscarnet
Risk of renal damage may increase.
NSAIDs: non-steroidal anti-inflammatory drugs, ACE: angiotensin-converting enzyme.
adverse gastrointestinal and bleeding-associated effects caused by COX-1 inhibition [13]. 
However, these drugs increase the risk of thrombosis and have been reported to have serious 
cardiovascular adverse effects, such as ischemic heart disease, heart failure, hypertension, and 
stroke. Therefore, COX-2 inhibitors should be used carefully, and dentists are advised to avoid 
these drugs in patients at high risk of cardiovascular disease [9]. Various COX-2 inhibitors 
(known as coxibs) have been developed; however, due to such cardiovascular side effects, some 
drugs, such as rofecoxib, have been withdrawn from the market. In Korea, celecoxib, etoricoxib, 
and polmacoxib are currently available. The anti-inflammatory, analgesic, and antipyretic 
effects of COX-2 inhibitors are reported to be similar to those of tNSAIDs.
CONCLUSION
When dentists prescribe analgesics in dental clinics, they should consider the severity of the 
patient's pain, the pharmacological properties of the drug, the patient's history of systemic 
disease, and potential interactions with drugs the patient is taking. Non-opioid analgesics 
have been shown to exhibit a safe profile when used for acute dental pain, and the overall 
risk of these drugs as they are used in dentistry is low. Considering the evidence regarding 
gastrointestinal and cardiovascular safety, acetaminophen, ibuprofen and naproxen appear 
to be the safest non-opioid drugs. A stepwise approach for the management of pain in dental 
practice is summarized in Table 4.
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Table 4. A stepwise approach for pain management in dental practice
Severity of pain Recommended drugs
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